

September 2020 Newsletter



September 2020 Research Spotlight

EVENTS



A New Podcast Series for People with MS

EMD Serono, in collaboration with Accelerated Cure Project, has released the first three podcasts in a 5-part educational podcast series, hosted by Jon Strum, called “Uncovering Sex in MS: A Dialogue About Sex, Parenthood and Hormones.” The topics covered in the podcast series were developed based on input from the [iConquerMS](#) community – another example of how iConquerMS members are driving and shaping MS research and care!

Women are nearly 3 times more likely to develop MS than men. Because the majority of these women are diagnosed during their childbearing years, clinicians and patients are encouraged to incorporate family-planning discussions into their ongoing MS management conversations. Optimal patient care involves coordination among a woman's neurologist, obstetrician/gynecologist, and primary care provider to ensure alignment on the woman's individual family-planning choices and preferences.

[Episode 1](#) features 3 unique perspectives on preconception planning for women with MS: Dr. Lori Travis, a neurologist who specializes in treating patients with MS; Dr. Erkan Buyuk, a reproductive endocrinologist, and Ms. Shannon Green, a pregnant woman living with MS.

Family planning is not just a concern for women with MS. Men with MS also need to be involved in these discussions. They have different concerns about fertility and pregnancy than women with MS. Thus, optimal MS care involves coordination and communication among a man's neurologist and other care team members, such as reproductive endocrinologists and urologists.

[Episode 2](#) features 3 unique perspectives on preconception planning for men with MS: Dr. Lori Travis, a neurologist who specializes in treating patients with MS; Dr. David Ryley, a reproductive endocrinologist with experience in treating men with MS; and Mr. Josh Evitt, a male patient with MS who has experienced fertility concerns during the family-planning process.

For pregnant women with MS, preparing for the birth of a child can be a time of excitement and anxiety. Each woman should work closely with her neurologist and other care team members to determine how best to manage her MS in the postpartum period. In addition to postpartum disease management, postpartum depression should also be assessed, because although the data are limited, it appears that new mothers with MS may have an increased risk of postpartum depression.

[Episode 3](#) features 3 unique perspectives on postpartum planning for new mothers with MS: Ms. Melanie Huff, a nurse practitioner who specializes in MS; Dr. Adam Kaplin, a mental health specialist; and Lindsey, a mother with MS who has first-hand experience with the postpartum period.

Stay tuned for future episodes!

RESEARCH OPPORTUNITIES



Call for Older Adults with Multiple Sclerosis

Are you 60 years or older and living with MS?

Are you interested in receiving the HALT MS Research Center Newsletters?

Do you want to know more about our events, research activities and findings, or general information about healthy aging and MS?

If the answers to these questions are **yes**, we invite you to take part in the HALT MS Registry.

What will you do?

You will be asked to register and provide your name and email address.

Why is this registry important?

During the HALT MS Research Center Symposium and Focus group, we learned that people with MS would like to have a channel for learning about our center activities such as new study findings, events, and general news of aging and MS, as examples. To that end, one purpose of this project is to establish a registry as an information dissemination mechanism for the HALT MS Research Center.

What's in it for me?

You will be helping us to build the registry that will be used to help us to communicate our research activities, events, and findings about aging and MS.

Will I be compensated for my time?

No, there will be no compensation for registration.

If you are interested in participating in this registry, **please click the link below or e-mail Trinh Huynh at enrl@uabmc.edu.**

https://uab.co1.qualtrics.com/jfe/form/SV_3RcRnwQVX6iptU9



Interviews with People Taking Vumerity®: Understanding Your Treatment Experience

Researchers are seeking 20 people in the U.S. with relapsing forms of Multiple Sclerosis including clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive disease (SPMS) to participate in a 1-hour telephone/online interview. The purpose of the interview is to gain insights from people about their experience when taking Vumerity® treatment. The results from this research will be used to gain a better understanding of patients' experiences with Vumerity® and inform how to better support current and future MS patients

Participants must have taken Vumerity® for at least 5 weeks within the past 6 months; participants may currently be taking Vumerity® or may have discontinued Vumerity® within the past 6 months.

If you are interested and meet these criteria, please submit your information here:

https://www.research.net/r/InterviewOp_AcelCure

(Copy this link into your browser if the link does not work)

All participants who complete the 1-hour interview will be compensated. Participation is strictly voluntary, and your responses will remain anonymous.

Endeavour provides research opportunities to patients, caregivers, and healthcare providers, helping organizations who research and develop therapies. By participating in research, your experiences, perspectives, and opinions help researchers better understand diseases and treatment effects from your point of view. For information about our privacy policy, visit <http://endeavour-clinical.com/privacy/>. For questions regarding this opportunity, email research@endeavour-clinical.com.



Real MS™ (Research Engagement About Life with MS)

In the summer of 2016, the iConquerMS initiative launched REAL MS, a longitudinal study of MS. REAL MS participants complete questionnaires online twice each year on a variety of subjects, including health history, diet, exercise and their experience with MS. A **ninth round** of REAL MS surveys are now available through the iConquerMS portal. Completing these surveys is one of the simplest ways you can accelerate MS research. The information collected will play a pivotal role in helping scientists and clinicians gain a better understanding of the health and quality of life over time for people with MS. REAL MS is just one of the many ways iConquerMS is facilitating research on topics of importance to people affected by the disease. If you are not already a member, please consider [joining](#) iConquerMS, the only people-powered research network for MS. Already a member? Please [log in](#) to your account and complete your open surveys!



New Year, New You

Study Title: Step for MS (Supervised versus Telerehab Exercise Program for People with Multiple Sclerosis)

Study Purpose:

New research shows that exercise is good for people with MS and may decrease symptoms and improve health and walking ability. An exercise study called *STEP for MS* will compare the outcomes of a 16-week exercise program conducted at home to a program conducted in a gym. The researchers conducting the study hope that the findings will make exercise and its benefits more available to people with MS who have problems walking.

This Study Involves:

Participants will exercise two times per week for about one hour each session for 16 weeks. A trained “coach” will help participants learn how to exercise and will provide encouragement throughout the program. Participants will take assessments before starting the program, two months into the program, at 16-weeks when the program ends, and at 6 and 12 months after starting the program.

Eligibility:

If you are between the ages of 18 and 65 years and you have Multiple Sclerosis you may qualify if you:


- Can **walk** but you have **some difficulty**, with or without a device
- **Do not exercise** regularly
- Have not had a **relapse** in the past month
- Can commit to **train 2 times a week for 16 weeks**
- Can **drive to study site** for assessments and potentially for exercise training
- Have reliable **internet access**

Participating Locations:

- Massachusetts General Hospital, Boston, MA (**new site now open!**)
Contact: Dr. Plumer 617-724-3103/ PPlummer@MGHIHP.EDU
- Shepherd Center, Atlanta, GA
Contact: Erica Sutton at 404-367-1305
- Cleveland Clinic, Mellen Center, Cleveland, OH
Contact: Darlene Stough at 216-445-5877/ stoughd@ccf.org
- University of Colorado, Denver
Contact: Alexa Vareldzis: neurologyresearchpartners@cuanschutz.edu / 303-724-4644
- University of Alabama, Birmingham
Contact: Petra Silic at 205-975-1306/ petra09@uab.edu
- University of Georgia, Athens
Contact: Megan Ware at 423-260-5045/ megan.ware20@uga.edu
- Marquette University, Milwaukee, WI
Contact: Heidi Feuling at 414-288-6209/ Heidi.feuling@marquette.edu
- University of North Carolina, Chapel Hill
Contact: Rachel Keen at 704-877-5636/ rayray@live.unc.edu

For more information, please visit our

website: <https://www.iconquerms.org/welcome-step-ms>



Share your experience with COVID-19

As a supporter of Accelerated Cure Project, you know one way to deal with the uncertainty of MS is to **act** – to be proactively involved in research and to contribute your insights, expertise, and information so that key questions about MS may be answered.

The COVID-19 crisis has added an additional level of complexity and urgency for those affected by MS.

In response, we have launched a survey on iConquerMS to learn more about how people affected by MS are dealing with the COVID-19 pandemic and what their personal experience has been with COVID-19.

We are interested in responses from all – those with and without MS, whether or not you have been diagnosed with COVID-19 – and hope the information gathered through this survey will help people affected by MS and their doctors during the current pandemic and in the case of future viral outbreaks.

Participating in the COVID-19 in MS study is easy. If you are not already a member, please consider [joining iConquerMS](#). Your voice matters! Already a member? Please [login](#) to your account and complete your COVID-19 survey. Thank you for your participation!

NEW RESEARCH RESULTS



The US Food and Drug Administration (FDA) recently approved [Kesimpta](#)[®] (ofatumumab) for the treatment of relapsing forms of MS in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Kesimpta is the first B-cell therapy that can be self-administered subcutaneously once monthly at home. Approval is based on results from the [ASCLEPIOS I and II studies](#) in which Kesimpta was shown to be more effective than teriflunomide in reducing relapse rate, disability progression, and the number of lesions on MRI. Kesimpta is now available in the United States.